TABLE 2.
Updated studies of liver transplantation for hilar cholangiocellular carcinoma
| First author | Report year | Country | Study design | Patient number | Medican Age (years) | PSC (%) | Tumor size (cm) | LDLT/DDLT/DLT | Median OS (months) | 1 year OS (%) | 3 years OS (%) | 5 years OS (%) | Recurrence rate (%) | Mortality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Single‐centre studies | ||||||||||||||
| Dondorf et al | 2018 | Germany | retrospective | n = 22 | 52.5 (30‐71) a | 2 (6%) | 3.8 (1.6‐8.5) a | 9/12/1 | 28.7 (4.8‐154.7) a | 78.2 | 32.1 | 24.1 | N/A | 13.6% (30‐day) |
| Loveday et al | 2017 | Canada | retrospective | n = 6 | 53.9 | N/A | N/A | 3/3/0 | N/A | 83.3 | N/A | N/A | 1/6 (16%) | N/A |
| (26.7‐62.8) a | ||||||||||||||
| Rosen | 2012 | USA | retrospective | n = 136 | N/A | 87 (64%) | N/A | 45/90/1 | N/A | 92 | 81 | 74 | 29/136 (21.3%) | N/A |
| Multicentric studies | ||||||||||||||
| Ethun et al | 2017 | USA | retrospective, multi center | n = 41 | 54 (43‐62) a | 25 (61%) | 2.5 (1.1‐5.0) a | N/A | N/A | 93 | 72 | 64 | 10/41 (24%) | 4.8% (90‐day) |
| Kaiser et al | 2008 | Germany | retrospective, multi center | n = 47 | N/A | 8 (17%) | N/A | N/A | 35.5 | 61 | 31 | 22 | 16/47 (34%) | 25.5% (30‐day) |
| Robles et al | 2004 | Spain | retrospective, multi center | n = 36 | 44 (20‐63) a | 3 (8%) | N/A | N/A | 55 ± 11 | 82 | 53 | 30 | 19/36 (53%) | 8.3% (90‐day) |
| 79 | 40.3 | 38 | 45/124 (36.3%) | 13.70% | ||||||||||
| Registry study | ||||||||||||||
| Salgia et al | 2013 | USA | retrospective, multi center | n = 359 | 49 (18‐71) a | 84 (23%) | N/A | 40/319/0 | 65(2‐251) a | 85.8 | 63.5 | 51.4 | N/A | N/A |
Abbreviations: N/A, not available; OS, overall survival.
a
Median value (Minimum value ‐ Maximum value).